PMID- 30819684
OWN - NLM
STAT- MEDLINE
DCOM- 20190415
LR  - 20190415
IS  - 1756-1833 (Electronic)
IS  - 0959-8138 (Linking)
VI  - 364
DP  - 2019 Feb 28
TI  - Diabetes insipidus.
PG  - l321
LID - 10.1136/bmj.l321 [doi]
FAU - Levy, Miles
AU  - Levy M
AD  - Department of Endocrinology, University Hospitals of Leicester, Leicester, UK.
FAU - Prentice, Malcolm
AU  - Prentice M
AD  - Department of Endocrinology, Croydon University Hospital, London, UK.
FAU - Wass, John
AU  - Wass J
AD  - Department of Endocrinology, Oxford University Hospital NHS Foundation Trust,
      Oxford, UK.
LA  - eng
PT  - Journal Article
PT  - Practice Guideline
DEP - 20190228
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
RN  - 0 (Antidiuretic Agents)
RN  - ENR1LLB0FP (Deamino Arginine Vasopressin)
SB  - AIM
SB  - IM
MH  - Antidiuretic Agents/therapeutic use
MH  - Deamino Arginine Vasopressin/administration & dosage/*therapeutic use
MH  - Diabetes Insipidus/*diagnosis/*drug therapy/epidemiology/physiopathology
MH  - Endocrinology/organization & administration
MH  - Humans
MH  - Male
MH  - Osmolar Concentration
MH  - Polydipsia/diagnosis/etiology
MH  - Polyuria/diagnosis/etiology
MH  - United Kingdom/epidemiology
MH  - Young Adult
COIS- Competing interestsThe BMJ has judged that there are no disqualifying financial
      ties to commercial companies. The authors declare the following other interests: 
      None. Further details of BMJ policy on financial interests is here:
      https://www.bmj.com/about-bmj/resources-authors/forms-policies-and-checklists/dec
      laration-competing-interests
EDAT- 2019/03/02 06:00
MHDA- 2019/04/16 06:00
CRDT- 2019/03/02 06:00
PHST- 2019/03/02 06:00 [entrez]
PHST- 2019/03/02 06:00 [pubmed]
PHST- 2019/04/16 06:00 [medline]
AID - 10.1136/bmj.l321 [doi]
PST - epublish
SO  - BMJ. 2019 Feb 28;364:l321. doi: 10.1136/bmj.l321.

PMID- 30467109
OWN - NLM
STAT- MEDLINE
DCOM- 20190225
LR  - 20190225
IS  - 1756-1833 (Electronic)
IS  - 0959-8138 (Linking)
VI  - 363
DP  - 2018 Nov 22
TI  - Are you well controlled?
PG  - k3119
LID - 10.1136/bmj.k3119 [doi]
FAU - Hendley, Judith
AU  - Hendley J
LA  - eng
PT  - Journal Article
DEP - 20181122
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
SB  - AIM
SB  - IM
MH  - Diabetes Mellitus, Type 2/prevention & control/*psychology
MH  - Humans
MH  - *Language
MH  - *Patient Rights
MH  - United Kingdom
COIS- Competing interests: Competing interests: The author's competing interests are
      held by the journal, and are not related to the content of this article.
EDAT- 2018/11/24 06:00
MHDA- 2019/02/26 06:00
CRDT- 2018/11/24 06:00
PHST- 2018/11/24 06:00 [entrez]
PHST- 2018/11/24 06:00 [pubmed]
PHST- 2019/02/26 06:00 [medline]
AID - 10.1136/bmj.k3119 [doi]
PST - epublish
SO  - BMJ. 2018 Nov 22;363:k3119. doi: 10.1136/bmj.k3119.

PMID- 30803028
OWN - NLM
STAT- Publisher
LR  - 20190313
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2019 Feb 25
TI  - Is it possible to constantly and accurately monitor blood sugar levels, in people
      with Type 1 diabetes, with a discrete device (non-invasive or invasive)?
LID - 10.1111/dme.13942 [doi]
AB  - Real-time continuous glucose monitors using subcutaneous needle-type sensors
      continue to develop. The limitations of currently available systems, however,
      include time lag behind changes in blood glucose, the invasive nature of such
      systems, and in some cases, their accuracy. Non-invasive techniques have been
      developed, but, to date, no commercial device has been successful. A key research
      priority for people with Type 1 diabetes identified by the James Lind Alliance
      was to identify ways of monitoring blood glucose constantly and accurately using 
      a discrete device, invasive or non-invasive. Integration of such a sensor is
      important in the development of a closed-loop system and the technology must be
      rapid, selective and acceptable for continuous use by individuals. The present
      review provides an update on existing continuous glucose-sensing technologies,
      and an overview of emergent techniques, including their accuracy and limitations.
CI  - (c) 2019 Diabetes UK.
FAU - Avari, P
AU  - Avari P
AUID- ORCID: https://orcid.org/0000-0001-9047-3589
AD  - Division of Diabetes, Endocrinology and Metabolism, Faculty of Medicine, Imperial
      College, London, UK.
FAU - Reddy, M
AU  - Reddy M
AD  - Division of Diabetes, Endocrinology and Metabolism, Faculty of Medicine, Imperial
      College, London, UK.
FAU - Oliver, N
AU  - Oliver N
AUID- ORCID: https://orcid.org/0000-0003-3525-3633
AD  - Division of Diabetes, Endocrinology and Metabolism, Faculty of Medicine, Imperial
      College, London, UK.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190225
PL  - England
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2019/02/26 06:00
MHDA- 2019/02/26 06:00
CRDT- 2019/02/26 06:00
PHST- 2019/02/22 00:00 [accepted]
PHST- 2019/02/26 06:00 [pubmed]
PHST- 2019/02/26 06:00 [medline]
PHST- 2019/02/26 06:00 [entrez]
AID - 10.1111/dme.13942 [doi]
PST - aheadofprint
SO  - Diabet Med. 2019 Feb 25. doi: 10.1111/dme.13942.

PMID- 30803019
OWN - NLM
STAT- Publisher
LR  - 20190408
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2019 Feb 25
TI  - Ceramides and diabetes mellitus: an update on the potential molecular
      relationships.
LID - 10.1111/dme.13943 [doi]
AB  - Recent evidence suggests that ceramides can play an important pathophysiological 
      role in the development of diabetes. Ceramides are primarily recognized as lipid 
      bilayer building blocks, but recent work has shown that these endogenous
      molecules are important intracellular signalling mediators and may exert some
      diabetogenic effects via molecular pathways involved in insulin resistance,
      beta-cell apoptosis and inflammation. In the present review, we consider the
      available evidence on the possible roles of ceramides in diabetes mellitus and
      introduce eight different molecular mechanisms mediating the diabetogenic action 
      of ceramides, categorized into those predominantly related to insulin resistance 
      vs those mainly implicated in beta-cell dysfunction. Specifically, the
      mechanistic evidence involves beta-cell apoptosis, pancreatic inflammation,
      mitochondrial stress, endoplasmic reticulum stress, adipokine release, insulin
      receptor substrate 1 phosphorylation, oxidative stress and insulin synthesis.
      Collectively, the evidence suggests that therapeutic agents aimed at reducing
      ceramide synthesis and lowering circulating levels may be beneficial in the
      prevention and/or treatment of diabetes and its related complications.
CI  - (c) 2019 Diabetes UK.
FAU - Yaribeygi, H
AU  - Yaribeygi H
AUID- ORCID: https://orcid.org/0000-0002-1706-6212
AD  - Chronic Kidney Disease Research Center, Shahid Beheshti University of Medical
      Sciences, Tehran, Iran.
FAU - Bo, S
AU  - Bo S
AD  - Department of Medical Sciences, AOU Citta della Salute e della Scienza di Torino,
      University of Turin, Torino, Italy.
FAU - Ruscica, M
AU  - Ruscica M
AD  - Dipartimento di Scienze Farmacologiche e Biomolecolari, Universita degli Studi di
      Milano, Milan, Italy.
FAU - Sahebkar, A
AU  - Sahebkar A
AUID- ORCID: https://orcid.org/0000-0002-8656-1444
AD  - Neurogenic Inflammation Research Center, Mashhad, Iran.
AD  - Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad,
      Iran.
AD  - School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190225
PL  - England
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2019/02/26 06:00
MHDA- 2019/02/26 06:00
CRDT- 2019/02/26 06:00
PHST- 2019/02/22 00:00 [accepted]
PHST- 2019/02/26 06:00 [pubmed]
PHST- 2019/02/26 06:00 [medline]
PHST- 2019/02/26 06:00 [entrez]
AID - 10.1111/dme.13943 [doi]
PST - aheadofprint
SO  - Diabet Med. 2019 Feb 25. doi: 10.1111/dme.13943.

PMID- 30801765
OWN - NLM
STAT- Publisher
LR  - 20190327
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2019 Feb 22
TI  - Non-insulin treatments for Type 1 diabetes: critical appraisal of the available
      evidence and insight into future directions.
LID - 10.1111/dme.13941 [doi]
AB  - Intensive insulin therapy is the mainstay of treatment for people with Type 1
      diabetes, but hypoglycaemia and weight gain are often limiting factors in
      achieving glycaemic targets and decreasing the risk of diabetes-related
      complications. The inclusion of pharmacological agents used traditionally in Type
      2 diabetes as adjuncts to insulin therapy in Type 1 diabetes has been explored,
      with the goal of mitigating such drawbacks. Pramlintide and metformin result in
      modest HbA1c and weight reductions, but their use is limited by poor tolerability
      and, in the case of pramlintide, by frequency of injections and cost. The
      addition of glucagon-like peptide-1 receptor agonists to insulin results in
      improved glycaemic control, reduced insulin doses and weight loss, but this is at
      the expense of higher rates of hypoglycaemia and hyperglycaemia with ketosis.
      Sodium-glucose co-transporter-2 and dual sodium-glucose co-transporter-2 and -1
      inhibitors also improve glucose control, but with reductions in weight and
      insulin requirements potentiating the risk of acidosis-related events and
      hypoglycaemia. The high proportion of people with Type 1 diabetes not achieving
      glycaemic targets, the negative clinical impact of intensive insulin therapy and 
      the rise in obesity and cardiovascular disease and mortality, underline the need 
      for individualized clinical care. The evaluation of new therapies, effective in
      Type 2 diabetes, as adjuncts to insulin therapy represents a promising strategy, 
      particularly given the beneficial effects on cardiovascular and renal outcomes in
      people with Type 2 diabetes with or at high risk of complications that are also
      observed in patients with Type 1 diabetes. As the population with Type 1 diabetes
      ages, our mission is to evolve and provide better tools and improved therapies to
      excel, not only in glycaemic control but also in risk reduction and reduction of 
      complications.
CI  - (c) 2019 Diabetes UK.
FAU - Wright, L A
AU  - Wright LA
AUID- ORCID: https://orcid.org/0000-0002-0092-361X
AD  - University of Washington Medical Center/Roosevelt, Seattle, WA, USA.
FAU - Hirsch, I B
AU  - Hirsch IB
AD  - University of Washington Medical Center/Roosevelt, Seattle, WA, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190222
PL  - England
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2019/02/26 06:00
MHDA- 2019/02/26 06:00
CRDT- 2019/02/26 06:00
PHST- 2019/02/21 00:00 [accepted]
PHST- 2019/02/26 06:00 [pubmed]
PHST- 2019/02/26 06:00 [medline]
PHST- 2019/02/26 06:00 [entrez]
AID - 10.1111/dme.13941 [doi]
PST - aheadofprint
SO  - Diabet Med. 2019 Feb 22. doi: 10.1111/dme.13941.

PMID- 30816853
OWN - NLM
STAT- In-Data-Review
LR  - 20190302
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
VI  - 68
IP  - 2
DP  - 2019 Feb
TI  - Statement of Retraction. Matilde Caruso, Claudia Miele, Andrea Oliva, Gerolama
      Condorelli, Francesco Oriente, Gabriele Riccardi, Brunella Capaldo, Francesca
      Fiory, Domenico Accili, Pietro Formisano, and Francesco Beguinot. The IR1152
      Mutant Insulin Receptor Selectively Impairs Insulin Action in Skeletal Muscle but
      Not in Liver. Diabetes 2000;49:1194-1202. DOI: 10.2337/diabetes.49.7.1194. PMID: 
      10909978.
PG  - 464
LID - 10.2337/db19-rt02a [doi]
CN  - American Diabetes Association
LA  - eng
PT  - Journal Article
PT  - Retraction of Publication
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
ROF - Diabetes. 2000 Jul;49(7):1194-202. PMID: 10909978
PMC - PMC6341298
EDAT- 2019/03/01 06:00
MHDA- 2019/03/01 06:00
CRDT- 2019/03/01 06:00
PHST- 2019/03/01 06:00 [entrez]
PHST- 2019/03/01 06:00 [pubmed]
PHST- 2019/03/01 06:00 [medline]
AID - 68/2/464 [pii]
AID - 10.2337/db19-rt02a [doi]
PST - ppublish
SO  - Diabetes. 2019 Feb;68(2):464. doi: 10.2337/db19-rt02a.

PMID- 30816852
OWN - NLM
STAT- In-Data-Review
LR  - 20190302
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
VI  - 68
IP  - 2
DP  - 2019 Feb
TI  - Statement of Retraction. Gerolama Condorelli, Giovanni Vigliotta, Alessandra
      Trencia, Maria Alessandra Maitan, Matilde Caruso, Claudia Miele, Francesco
      Oriente, Stefania Santopietro, Pietro Formisano, and Francesco Beguinot. Protein 
      Kinase C (PKC)-alpha Activation Inhibits PKC-zeta and Mediates the Action of
      PED/PEA-15 on Glucose Transport in the L6 Skeletal Muscle Cells. Diabetes
      2001;50:1244-1252. DOI: 10.2337/diabetes.50.6.1244. PMID: 11375323.
PG  - 464-465
LID - 10.2337/db19-rt02b [doi]
CN  - American Diabetes Association
LA  - eng
PT  - Journal Article
PT  - Retraction of Publication
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
ROF - Diabetes. 2001 Jun;50(6):1244-52. PMID: 11375323
PMC - PMC6341296
EDAT- 2019/03/01 06:00
MHDA- 2019/03/01 06:00
CRDT- 2019/03/01 06:00
PHST- 2019/03/01 06:00 [entrez]
PHST- 2019/03/01 06:00 [pubmed]
PHST- 2019/03/01 06:00 [medline]
AID - 68/2/464-a [pii]
AID - 10.2337/db19-rt02b [doi]
PST - ppublish
SO  - Diabetes. 2019 Feb;68(2):464-465. doi: 10.2337/db19-rt02b.

PMID- 30796029
OWN - NLM
STAT- Publisher
LR  - 20190411
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
DP  - 2019 Feb 22
TI  - The Hypothalamic Arcuate Nucleus-Median Eminence is a Target for Sustained
      Diabetes Remission Induced by Fibroblast Growth Factor 1.
LID - db190025 [pii]
LID - 10.2337/db19-0025 [doi]
AB  - In rodent models of type 2 diabetes (T2D), sustained remission of diabetic
      hyperglycemia can be induced by a single intracerebroventricular (icv) injection 
      of fibroblast growth factor 1 (FGF1). To identify the brain area(s) responsible
      for this effect, we first used immunohistochemistry to map the hypothalamic
      distribution of phosphoERK (pERK1/2), a marker of MAP kinase-ERK signal
      transduction downstream of FGF receptor activation. Twenty minutes after icv FGF1
      injection in adult male Wistar rats, pERK1/2 staining was detected primarily in
      two hypothalamic areas: the arcuate nucleus and adjacent median eminence
      (ARC-ME), and the paraventricular nucleus (PVN). To determine whether an action
      of FGF1 localized to either the ARC-ME or the PVN is capable of mimicking the
      sustained antidiabetic effect elicited by icv FGF1, we microinjected either
      saline vehicle or a low dose of FGF1 (0.3 microg/side) bilaterally into either
      the ARC-ME area or PVN of Zucker Diabetic Fatty (ZDF) rats, a model of T2D, and
      monitored daily food intake, body weight, and blood glucose levels over a 3-week 
      period. Whereas bilateral intra-arcuate microinjection of saline vehicle was
      without effect, remission of hyperglycemia lasting >3 wk was observed following
      bilateral microinjection of FGF1 into the ARC-ME. This antidiabetic effect cannot
      be attributed to leakage of FGF1 into cerebrospinal fluid and subsequent action
      on other brain areas, since icv injection of the same total dose was without
      effect. Combined with our finding that bilateral microinjection of the same dose 
      of FGF1 into the PVN was without effect on glycemia or other parameters, we
      conclude that the ARC-ME area (but not the PVN) is a target for sustained
      remission of diabetic hyperglycemia induced by FGF1.
CI  - (c) 2019 by the American Diabetes Association.
FAU - Brown, Jenny M
AU  - Brown JM
AD  - University of Washington Medicine Diabetes Institute, Department of Medicine,
      University of Washington, Seattle, WA, USA.
FAU - Scarlett, Jarrad M
AU  - Scarlett JM
AD  - University of Washington Medicine Diabetes Institute, Department of Medicine,
      University of Washington, Seattle, WA, USA.
AD  - Department of Pediatric Gastroenterology and Hepatology, University of
      Washington, Seattle, WA, USA.
FAU - Matsen, Miles E
AU  - Matsen ME
AD  - University of Washington Medicine Diabetes Institute, Department of Medicine,
      University of Washington, Seattle, WA, USA.
FAU - Nguyen, Hong T
AU  - Nguyen HT
AD  - University of Washington Medicine Diabetes Institute, Department of Medicine,
      University of Washington, Seattle, WA, USA.
FAU - Secher, Anna
AU  - Secher A
AD  - Diabetes Research, Global Drug Discovery, Novo Nordisk, Maaleov, Denmark.
FAU - Jorgensen, Rasmus
AU  - Jorgensen R
AD  - Diabetes Research, Global Drug Discovery, Novo Nordisk, Maaleov, Denmark.
FAU - Morton, Gregory J
AU  - Morton GJ
AD  - University of Washington Medicine Diabetes Institute, Department of Medicine,
      University of Washington, Seattle, WA, USA.
FAU - Schwartz, Michael W
AU  - Schwartz MW
AD  - University of Washington Medicine Diabetes Institute, Department of Medicine,
      University of Washington, Seattle, WA, USA. mschwart@u.washington.edu.
LA  - eng
GR  - K08 DK114474/DK/NIDDK NIH HHS/United States
GR  - R01 DK101997/DK/NIDDK NIH HHS/United States
PT  - Journal Article
DEP - 20190222
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
EDAT- 2019/02/24 06:00
MHDA- 2019/02/24 06:00
CRDT- 2019/02/24 06:00
PHST- 2019/01/08 00:00 [received]
PHST- 2019/02/14 00:00 [accepted]
PHST- 2019/02/24 06:00 [entrez]
PHST- 2019/02/24 06:00 [pubmed]
PHST- 2019/02/24 06:00 [medline]
AID - db19-0025 [pii]
AID - 10.2337/db19-0025 [doi]
PST - aheadofprint
SO  - Diabetes. 2019 Feb 22. pii: db19-0025. doi: 10.2337/db19-0025.

PMID- 30811342
OWN - NLM
STAT- MEDLINE
DCOM- 20190306
LR  - 20190306
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 42
IP  - 1
DP  - 2019 Jan
TI  - Response to Comment on Umpierrez and Klonoff. Diabetes Technology Update: Use of 
      Insulin Pumps and Continuous Glucose Monitoring in the Hospital. Diabetes Care
      2018;41:1579-1589.
PG  - e15
LID - 10.2337/dci18-0043 [doi]
FAU - Umpierrez, Guillermo E
AU  - Umpierrez GE
AUID- ORCID: 0000-0002-3252-5026
AD  - Division of Endocrinology, Metabolism and Lipids, Department of Medicine, Emory
      University School of Medicine, Atlanta, GA geumpie@emory.edu.
FAU - Klonoff, David C
AU  - Klonoff DC
AUID- ORCID: 0000-0002-0624-698X
AD  - Diabetes Research Institute, Mills-Peninsula Medical Center, San Mateo, CA.
LA  - eng
PT  - Letter
PT  - Comment
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
RN  - 0 (Blood Glucose)
RN  - 0 (Insulins)
SB  - IM
CON - Diabetes Care. 2018 Aug;41(8):1579-1589. PMID: 29936424
CON - Diabetes Care. 2019 Jan;42(1):e14. PMID: 30811341
MH  - *Blood Glucose
MH  - Blood Glucose Self-Monitoring
MH  - *Diabetes Mellitus, Type 1
MH  - Humans
MH  - Insulin Infusion Systems
MH  - Insulins
EDAT- 2019/02/28 06:00
MHDA- 2019/03/07 06:00
CRDT- 2019/02/28 06:00
PHST- 2019/02/28 06:00 [entrez]
PHST- 2019/02/28 06:00 [pubmed]
PHST- 2019/03/07 06:00 [medline]
AID - 42/1/e15 [pii]
AID - 10.2337/dci18-0043 [doi]
PST - ppublish
SO  - Diabetes Care. 2019 Jan;42(1):e15. doi: 10.2337/dci18-0043.

PMID- 30811341
OWN - NLM
STAT- MEDLINE
DCOM- 20190306
LR  - 20190306
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 42
IP  - 1
DP  - 2019 Jan
TI  - Comment on Umpierrez and Klonoff. Diabetes Technology Update: Use of Insulin
      Pumps and Continuous Glucose Monitoring in the Hospital. Diabetes Care
      2018;41:1579-1589.
PG  - e14
LID - 10.2337/dc18-1929 [doi]
FAU - Delgado-Hurtado, Juan Jose
AU  - Delgado-Hurtado JJ
AUID- ORCID: 0000-0003-1445-0232
AD  - Endocrinology, Diabetes and Metabolism, Dartmouth-Hitchcock Medical Center,
      Lebanon, NH juan.j.delgado.hurtado@hitchcock.org.
FAU - Armstrong, Alicia
AU  - Armstrong A
AD  - Endocrinology, Diabetes and Metabolism, Dartmouth-Hitchcock Medical Center,
      Lebanon, NH.
FAU - Chaidarun, Sushela
AU  - Chaidarun S
AD  - Endocrinology, Diabetes and Metabolism, Dartmouth-Hitchcock Medical Center,
      Lebanon, NH.
LA  - eng
PT  - Letter
PT  - Comment
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
RN  - 0 (Blood Glucose)
RN  - 0 (Insulins)
SB  - IM
CON - Diabetes Care. 2018 Aug;41(8):1579-1589. PMID: 29936424
CIN - Diabetes Care. 2019 Jan;42(1):e15. PMID: 30811342
MH  - *Blood Glucose
MH  - Blood Glucose Self-Monitoring
MH  - *Diabetes Mellitus, Type 1
MH  - Humans
MH  - Insulin Infusion Systems
MH  - Insulins
EDAT- 2019/02/28 06:00
MHDA- 2019/03/07 06:00
CRDT- 2019/02/28 06:00
PHST- 2019/02/28 06:00 [entrez]
PHST- 2019/02/28 06:00 [pubmed]
PHST- 2019/03/07 06:00 [medline]
AID - 42/1/e14 [pii]
AID - 10.2337/dc18-1929 [doi]
PST - ppublish
SO  - Diabetes Care. 2019 Jan;42(1):e14. doi: 10.2337/dc18-1929.

PMID- 30811340
OWN - NLM
STAT- MEDLINE
DCOM- 20190306
LR  - 20190306
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 42
IP  - 1
DP  - 2019 Jan
TI  - Response to Comment on Cheung and Moses. Gestational Diabetes Mellitus: Is It
      Time to Reconsider the Diagnostic Criteria? Diabetes Care 2018;41:1337-1338.
PG  - e13
LID - 10.2337/dci18-0045 [doi]
FAU - Cheung, N Wah
AU  - Cheung NW
AUID- ORCID: 0000-0001-6323-8006
AD  - Department of Diabetes and Endocrinology, Westmead Hospital, Sydney, New South
      Wales, Australia wah.cheung@sydney.edu.au.
AD  - Faculty of Medicine, University of Sydney, Sydney, New South Wales, Australia.
FAU - Moses, Robert G
AU  - Moses RG
AUID- ORCID: 0000-0003-4177-9105
AD  - Diabetes Services, Illawarra Shoalhaven Local Health District, Wollongong, New
      South Wales, Australia.
LA  - eng
PT  - Letter
PT  - Comment
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
SB  - IM
CON - Diabetes Care. 2018 Jul;41(7):1337-1338. PMID: 29934476
CON - Diabetes Care. 2019 Jan;42(1):e11-e12. PMID: 30811339
MH  - *Diabetes, Gestational
MH  - Female
MH  - Glucose Tolerance Test
MH  - Humans
MH  - *Hypertension, Pregnancy-Induced
MH  - Pregnancy
EDAT- 2019/02/28 06:00
MHDA- 2019/03/07 06:00
CRDT- 2019/02/28 06:00
PHST- 2019/02/28 06:00 [entrez]
PHST- 2019/02/28 06:00 [pubmed]
PHST- 2019/03/07 06:00 [medline]
AID - 42/1/e13 [pii]
AID - 10.2337/dci18-0045 [doi]
PST - ppublish
SO  - Diabetes Care. 2019 Jan;42(1):e13. doi: 10.2337/dci18-0045.

PMID- 30811339
OWN - NLM
STAT- MEDLINE
DCOM- 20190306
LR  - 20190306
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 42
IP  - 1
DP  - 2019 Jan
TI  - Comment on Cheung and Moses. Gestational Diabetes Mellitus: Is It Time to
      Reconsider the Diagnostic Criteria? Diabetes Care 2018;41:1337-1338.
PG  - e11-e12
LID - 10.2337/dc18-1941 [doi]
FAU - Sacks, David A
AU  - Sacks DA
AD  - Department of Research and Evaluation, Southern California Kaiser Permanente,
      Pasadena, CA david.a.sacks@kp.org.
LA  - eng
PT  - Letter
PT  - Comment
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
SB  - IM
CON - Diabetes Care. 2018 Jul;41(7):1337-1338. PMID: 29934476
CIN - Diabetes Care. 2019 Jan;42(1):e13. PMID: 30811340
MH  - *Diabetes, Gestational
MH  - Female
MH  - Glucose Tolerance Test
MH  - Humans
MH  - *Hypertension, Pregnancy-Induced
MH  - Pregnancy
EDAT- 2019/02/28 06:00
MHDA- 2019/03/07 06:00
CRDT- 2019/02/28 06:00
PHST- 2019/02/28 06:00 [entrez]
PHST- 2019/02/28 06:00 [pubmed]
PHST- 2019/03/07 06:00 [medline]
AID - 42/1/e11 [pii]
AID - 10.2337/dc18-1941 [doi]
PST - ppublish
SO  - Diabetes Care. 2019 Jan;42(1):e11-e12. doi: 10.2337/dc18-1941.

PMID- 30811338
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20190306
LR  - 20190306
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 42
IP  - 1
DP  - 2019 Jan
TI  - Response to Comment on Li et al. Visual Inspection of Chromatograms Assists
      Interpretation of HbA1c: A Case Report. Diabetes Care 2018;41:1829-1830.
PG  - e10
LID - 10.2337/dci18-0038 [doi]
FAU - Li, Qianrui
AU  - Li Q
AD  - Department of Endocrinology and Metabolism, West China Hospital, Sichuan
      University, Chengdu, China.
AD  - Institute of Health Informatics, University College London, London, U.K.
FAU - Xiao, Yuling
AU  - Xiao Y
AD  - Department of Laboratory Medicine, West China Hospital, Sichuan University,
      Chengdu, China.
FAU - Shah, Anoop Dinesh
AU  - Shah AD
AD  - Institute of Health Informatics, University College London, London, U.K.
AD  - University College London Hospitals NHS Foundation Trust, London, U.K.
FAU - Li, Sheyu
AU  - Li S
AUID- ORCID: 0000-0003-0060-0287
AD  - Department of Endocrinology and Metabolism, West China Hospital, Sichuan
      University, Chengdu, China lisheyu@gmail.com.
AD  - Division of Population Health and Genomics, Ninewells Hospital and Medical
      School, University of Dundee, Dundee, U.K.
LA  - eng
PT  - Letter
PT  - Research Support, Non-U.S. Gov't
PT  - Comment
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
CON - Diabetes Care. 2018 Aug;41(8):1829-1830. PMID: 30030259
CON - Diabetes Care. 2019 Jan;42(1):e9. PMID: 30811337
EDAT- 2019/02/28 06:00
MHDA- 2019/02/28 06:01
CRDT- 2019/02/28 06:00
PHST- 2019/02/28 06:00 [entrez]
PHST- 2019/02/28 06:00 [pubmed]
PHST- 2019/02/28 06:01 [medline]
AID - 42/1/e10 [pii]
AID - 10.2337/dci18-0038 [doi]
PST - ppublish
SO  - Diabetes Care. 2019 Jan;42(1):e10. doi: 10.2337/dci18-0038.

PMID- 30811337
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20190306
LR  - 20190306
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 42
IP  - 1
DP  - 2019 Jan
TI  - Comment on Li et al. Visual Inspection of Chromatograms Assists Interpretation of
      HbA1c: A Case Report. Diabetes Care 2018;41:1829-1830.
PG  - e9
LID - 10.2337/dc18-1836 [doi]
FAU - Li, Jie
AU  - Li J
AD  - Department of Laboratory Medicine, Peking University Shenzhen Hospital, Shenzhen,
      Guangdong, China.
FAU - Lei, Jie
AU  - Lei J
AD  - Department of Laboratory Medicine, Maternity and Child Healthcare Hospital of
      Nanshan District, Shenzhen, Guangdong, China.
FAU - Xu, An-Ping
AU  - Xu AP
AD  - Department of Laboratory Medicine, Peking University Shenzhen Hospital, Shenzhen,
      Guangdong, China.
FAU - Xia, Yong
AU  - Xia Y
AD  - Department of Laboratory Medicine, Peking University Shenzhen Hospital, Shenzhen,
      Guangdong, China.
FAU - Ji, Ling
AU  - Ji L
AUID- ORCID: 0000-0003-4088-2514
AD  - Department of Laboratory Medicine, Peking University Shenzhen Hospital, Shenzhen,
      Guangdong, China 1120303921@qq.com.
LA  - eng
PT  - Letter
PT  - Comment
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
CON - Diabetes Care. 2018 Aug;41(8):1829-1830. PMID: 30030259
CIN - Diabetes Care. 2019 Jan;42(1):e10. PMID: 30811338
EDAT- 2019/02/28 06:00
MHDA- 2019/02/28 06:01
CRDT- 2019/02/28 06:00
PHST- 2019/02/28 06:00 [entrez]
PHST- 2019/02/28 06:00 [pubmed]
PHST- 2019/02/28 06:01 [medline]
AID - 42/1/e9 [pii]
AID - 10.2337/dc18-1836 [doi]
PST - ppublish
SO  - Diabetes Care. 2019 Jan;42(1):e9. doi: 10.2337/dc18-1836.

PMID- 30811336
OWN - NLM
STAT- MEDLINE
DCOM- 20190306
LR  - 20190306
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 42
IP  - 1
DP  - 2019 Jan
TI  - Comment on Wang et al. Incretin-Based Therapies and Diabetic Retinopathy:
      Real-World Evidence in Older U.S. Adults. Diabetes Care 2018;41:1998-2009.
PG  - e8
LID - 10.2337/dc18-1825 [doi]
FAU - Feldman-Billard, Sylvie
AU  - Feldman-Billard S
AUID- ORCID: 0000-0001-6994-8092
AD  - Department of Internal Medicine, Centre Hospitalier National d'Ophtalmologie des 
      Quinze-Vingts, Paris, France sfeldman@15-20.fr.
LA  - eng
PT  - Letter
PT  - Comment
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
RN  - 0 (Incretins)
SB  - IM
CON - Diabetes Care. 2018 Sep;41(9):1998-2009. PMID: 30012674
MH  - Adult
MH  - Diabetes Mellitus, Type 2
MH  - *Diabetic Nephropathies
MH  - *Diabetic Retinopathy
MH  - Humans
MH  - Incretins
EDAT- 2019/02/28 06:00
MHDA- 2019/03/07 06:00
CRDT- 2019/02/28 06:00
PHST- 2019/02/28 06:00 [entrez]
PHST- 2019/02/28 06:00 [pubmed]
PHST- 2019/03/07 06:00 [medline]
AID - 42/1/e8 [pii]
AID - 10.2337/dc18-1825 [doi]
PST - ppublish
SO  - Diabetes Care. 2019 Jan;42(1):e8. doi: 10.2337/dc18-1825.

PMID- 30811335
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20190329
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 42
IP  - 1
DP  - 2019 Jan
TI  - HbA1c, Insulin Resistance, and beta-Cell Function in Relation to Cognitive
      Function in Type 2 Diabetes: The CAROLINA Cognition Substudy.
PG  - e1-e3
LID - 10.2337/DC18-0914 [doi]
FAU - Janssen, Jolien
AU  - Janssen J
AUID- ORCID: 0000-0002-7742-0746
AD  - Department of Neurology, Brain Center Rudolf Magnus, University Medical Center
      Utrecht, Utrecht, the Netherlands j.janssen-9@umcutrecht.nl.
AD  - Julius Center for Health Sciences and Primary Care, University Medical Center
      Utrecht, Utrecht, the Netherlands.
FAU - van den Berg, Esther
AU  - van den Berg E
AD  - Department of Neurology, Brain Center Rudolf Magnus, University Medical Center
      Utrecht, Utrecht, the Netherlands.
AD  - Department of Neurology, Erasmus MC University Medical Center, Rotterdam, the
      Netherlands.
FAU - Zinman, Bernard
AU  - Zinman B
AUID- ORCID: 0000-0002-0041-1876
AD  - Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, and Division of
      Endocrinology, University of Toronto, Toronto, Canada.
FAU - Espeland, Mark A
AU  - Espeland MA
AD  - Department of Biostatistics and Data Science, Wake Forest School of Medicine,
      Winston-Salem, NC.
FAU - Geijselaers, Stefan L C
AU  - Geijselaers SLC
AD  - Department of Neurology, Brain Center Rudolf Magnus, University Medical Center
      Utrecht, Utrecht, the Netherlands.
AD  - Department of Internal Medicine and Cardiovascular Research Institute, Maastricht
      University Medical Center+, Maastricht, the Netherlands.
FAU - Mattheus, Michaela
AU  - Mattheus M
AD  - Global Biometrics and Data Management, Boehringer Ingelheim, Ingelheim, Germany.
FAU - Johansen, Odd Erik
AU  - Johansen OE
AD  - Clinical Development, Therapeutic Area CardioMetabolic, Boehringer Ingelheim,
      Asker, Norway.
FAU - Biessels, Geert Jan
AU  - Biessels GJ
AD  - Department of Neurology, Brain Center Rudolf Magnus, University Medical Center
      Utrecht, Utrecht, the Netherlands.
LA  - eng
SI  - ClinicalTrials.gov/NCT01243424
GR  - P30 AG049638/AG/NIA NIH HHS/United States
PT  - Letter
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2019/02/28 06:00
MHDA- 2019/02/28 06:01
CRDT- 2019/02/28 06:00
PHST- 2018/04/26 00:00 [received]
PHST- 2018/10/08 00:00 [accepted]
PHST- 2019/02/28 06:00 [entrez]
PHST- 2019/02/28 06:00 [pubmed]
PHST- 2019/02/28 06:01 [medline]
AID - 42/1/e1 [pii]
AID - 10.2337/DC18-0914 [doi]
PST - ppublish
SO  - Diabetes Care. 2019 Jan;42(1):e1-e3. doi: 10.2337/DC18-0914.

PMID- 30811333
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20190305
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 42
IP  - 1
DP  - 2019 Jan
TI  - In This Issue of Diabetes Care.
PG  - 1-2
LID - 10.2337/dc19-ti01 [doi]
LA  - eng
PT  - Introductory Journal Article
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2019/02/28 06:00
MHDA- 2019/02/28 06:01
CRDT- 2019/02/28 06:00
PHST- 2019/02/28 06:00 [entrez]
PHST- 2019/02/28 06:00 [pubmed]
PHST- 2019/02/28 06:01 [medline]
AID - 42/1/1 [pii]
AID - 10.2337/dc19-ti01 [doi]
PST - ppublish
SO  - Diabetes Care. 2019 Jan;42(1):1-2. doi: 10.2337/dc19-ti01.

PMID- 30796112
OWN - NLM
STAT- Publisher
LR  - 20190223
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2019 Feb 22
TI  - Improved Open-Loop Glucose Control With Basal Insulin Reduction 90 Minutes Before
      Aerobic Exercise in Patients With Type 1 Diabetes on Continuous Subcutaneous
      Insulin Infusion.
LID - dc182204 [pii]
LID - 10.2337/dc18-2204 [doi]
AB  - OBJECTIVE: To reduce exercise-associated hypoglycemia, individuals with type 1
      diabetes on continuous subcutaneous insulin infusion typically perform basal rate
      reductions (BRRs) and/or carbohydrate feeding, although the timing and amount of 
      BRRs necessary to prevent hypoglycemia are unclear. The goal of this study was to
      determine if BRRs set 90 min pre-exercise better attenuate hypoglycemia versus
      pump suspension (PS) at exercise onset. RESEARCH DESIGN AND METHODS: Seventeen
      individuals completed three 60-min treadmill exercise ( approximately 50% of
      VO2peak) visits in a randomized crossover design. The insulin strategies
      included: 1) PS at exercise onset; 2) 80% BRR set 90 min pre-exercise; and 3) 50%
      BRR set 90 min pre-exercise. RESULTS: Blood glucose level at exercise onset was
      higher with 50% BRR (191 +/- 49 mg/dL) vs. 80% BRR (164 +/- 41 mg/dL; P < 0.001) 
      and PS (164 +/- 45 mg/dL; P < 0.001). By exercise end, 80% BRR showed the
      smallest drop (-31 +/- 58 mg/dL) vs. 50% BRR (-47 +/- 50 mg/dL; P = 0.04) and PS 
      (-67 +/- 41 mg/dL; P < 0.001). With PS, 7 out of 17 participants developed
      hypoglycemia versus 1 out of 17 in both BRR conditions (P < 0.05). Following a
      standardized meal postexercise, glucose rose with PS and 50% BRR (both P < 0.05),
      but failed to rise with 80% BRR (P = 0.16). Based on interstitial glucose,
      overnight mean percent time in range was 83%, 83%, and 78%, and time in
      hypoglycemia was 2%, 1%, and 5% with 80% BRR, 50% BRR, and PS, respectively (all 
      P > 0.05). CONCLUSIONS: Overall, a 50-80% BRR set 90 min pre-exercise improves
      glucose control and decreases hypoglycemia risk during exercise better than PS at
      exercise onset, while not compromising the postexercise meal glucose control.
CI  - (c) 2019 by the American Diabetes Association.
FAU - Zaharieva, Dessi P
AU  - Zaharieva DP
AD  - Faculty of Health, School of Kinesiology and Health Science, Muscle Health
      Research Centre, York University, Toronto, Ontario, Canada.
FAU - McGaugh, Sarah
AU  - McGaugh S
AD  - Faculty of Health, School of Kinesiology and Health Science, Muscle Health
      Research Centre, York University, Toronto, Ontario, Canada.
FAU - Pooni, Rubin
AU  - Pooni R
AD  - Faculty of Health, School of Kinesiology and Health Science, Muscle Health
      Research Centre, York University, Toronto, Ontario, Canada.
FAU - Vienneau, Todd
AU  - Vienneau T
AD  - Insulet Canada Corporation, Oakville, Ontario, Canada.
FAU - Ly, Trang
AU  - Ly T
AD  - Insulet Corporation, Billerica, MA.
FAU - Riddell, Michael C
AU  - Riddell MC
AUID- ORCID: http://orcid.org/0000-0001-6556-7559
AD  - Faculty of Health, School of Kinesiology and Health Science, Muscle Health
      Research Centre, York University, Toronto, Ontario, Canada mriddell@yorku.ca.
AD  - LMC Diabetes & Endocrinology, Toronto, Ontario, Canada.
LA  - eng
PT  - Journal Article
DEP - 20190222
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2019/02/24 06:00
MHDA- 2019/02/24 06:00
CRDT- 2019/02/24 06:00
PHST- 2018/10/23 00:00 [received]
PHST- 2019/01/29 00:00 [accepted]
PHST- 2019/02/24 06:00 [entrez]
PHST- 2019/02/24 06:00 [pubmed]
PHST- 2019/02/24 06:00 [medline]
AID - dc18-2204 [pii]
AID - 10.2337/dc18-2204 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2019 Feb 22. pii: dc18-2204. doi: 10.2337/dc18-2204.

PMID- 30796111
OWN - NLM
STAT- Publisher
LR  - 20190329
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2019 Feb 22
TI  - Body Composition and Diabetes Risk in South Asians: Findings From the MASALA and 
      MESA Studies.
LID - dc181510 [pii]
LID - 10.2337/dc18-1510 [doi]
AB  - OBJECTIVE: South Asians have a higher prevalence of type 2 diabetes compared with
      other race/ethnic groups. Body composition is associated with the risk for type 2
      diabetes. Differences in body composition between South Asians and other
      race/ethnic groups are one hypothesized mechanism to explain the disproportionate
      prevalence of type 2 diabetes in this population. RESEARCH DESIGN AND METHODS:
      This study used data from the Mediators of Atherosclerosis in South Asians Living
      in America (MASALA) and the Multi-Ethnic Study of Atherosclerosis (MESA) cohorts 
      to determine whether body composition mediated the elevated prevalence of
      impaired fasting glucose and type 2 diabetes in South Asians. Participants (n =
      2,615) with complete body composition data were included. Ordinal logistic
      regression models were calculated to determine the odds for glycemic impairment
      in South Asians compared with the MESA cohort. RESULTS: In multivariate models,
      South Asians had a significantly higher prevalence of glycemic impairment and
      type 2 diabetes compared with all four race/ethnic groups included in the MESA (P
      < 0.001 for all). In unadjusted and multivariate adjusted models, South Asians
      had higher odds for impaired fasting glucose and type 2 diabetes compared with
      all other race/ethnic groups (P < 0.001 for all). The addition of body
      composition measures did not significantly mitigate this relationship.
      CONCLUSIONS: We did not identify strong evidence that accounting for body
      composition explains differences in the risk for type 2 diabetes. Future
      prospective studies of the MESA and MASALA cohorts are needed to understand how
      adipose tissue impacts the risk for type 2 diabetes and how to best assess this
      risk.
CI  - (c) 2019 by the American Diabetes Association.
FAU - Flowers, Elena
AU  - Flowers E
AUID- ORCID: http://orcid.org/0000-0002-7054-7533
AD  - University of California, San Francisco, Department of Physiological Nursing, San
      Francisco, CA elena.flowers@ucsf.edu.
AD  - University of California, San Francisco, Institute for Human Genetics, San
      Francisco, CA.
FAU - Lin, Feng
AU  - Lin F
AD  - University of California, San Francisco, Department of Epidemiology and
      Biostatistics, San Francisco, CA.
FAU - Kandula, Namratha R
AU  - Kandula NR
AD  - Northwestern University Feinberg School of Medicine, Department of Medicine,
      Chicago, IL.
FAU - Allison, Matthew
AU  - Allison M
AD  - University of California, San Diego, Department of Family Medicine and Public
      Health, San Diego, CA.
FAU - Carr, Jeffrey J
AU  - Carr JJ
AD  - Vanderbilt University, Department of Radiology and Radiological Sciences,
      Nashville, TN.
FAU - Ding, Jingzhong
AU  - Ding J
AD  - Wake Forest School of Medicine, Department of Internal Medicine, Section of
      Gerontology and Geriatric Medicine, Winston-Salem, NC.
FAU - Shah, Ravi
AU  - Shah R
AD  - Massachusetts General Hospital, Division of Cardiology, Boston, MA.
FAU - Liu, Kiang
AU  - Liu K
AD  - Northwestern University Feinberg School of Medicine, Department of Preventive
      Medicine, Chicago, IL.
FAU - Herrington, David
AU  - Herrington D
AD  - Wake Forrest University, Department of Internal Medicine, Section on
      Cardiovascular Medicine, Winston-Salem, NC.
FAU - Kanaya, Alka M
AU  - Kanaya AM
AD  - University of California, San Francisco, Department of Epidemiology and
      Biostatistics, San Francisco, CA.
AD  - University of California, San Francisco, Department of Medicine, Division of
      General Internal Medicine, San Francisco, CA.
LA  - eng
GR  - R01 HL093009/HL/NHLBI NIH HHS/United States
GR  - K24 HL112827/HL/NHLBI NIH HHS/United States
GR  - P30 DK098722/DK/NIDDK NIH HHS/United States
GR  - P30 DK092924/DK/NIDDK NIH HHS/United States
GR  - UL1 TR000004/TR/NCATS NIH HHS/United States
PT  - Journal Article
DEP - 20190222
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2019/02/24 06:00
MHDA- 2019/02/24 06:00
CRDT- 2019/02/24 06:00
PHST- 2018/07/13 00:00 [received]
PHST- 2019/01/16 00:00 [accepted]
PHST- 2019/02/24 06:00 [entrez]
PHST- 2019/02/24 06:00 [pubmed]
PHST- 2019/02/24 06:00 [medline]
AID - dc18-1510 [pii]
AID - 10.2337/dc18-1510 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2019 Feb 22. pii: dc18-1510. doi: 10.2337/dc18-1510.

PMID- 30796110
OWN - NLM
STAT- In-Data-Review
LR  - 20190321
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 42
IP  - 4
DP  - 2019 Apr
TI  - Effects of Light Therapy on Mood and Insulin Sensitivity in Patients With Type 2 
      Diabetes and Depression: Results From a Randomized Placebo-Controlled Trial.
PG  - 529-538
LID - 10.2337/dc18-1732 [doi]
AB  - OBJECTIVE: Depression is common in patients with type 2 diabetes and adversely
      affects quality of life and diabetes outcomes. We assessed whether light therapy,
      an antidepressant, improves mood and insulin sensitivity in patients with
      depression and type 2 diabetes. RESEARCH DESIGN AND METHODS: This randomized,
      double-blind, placebo-controlled trial included 83 patients with depression and
      type 2 diabetes. The intervention comprised 4 weeks of light therapy (10,000 lux)
      or placebo light therapy daily at home. Primary outcomes included depressive
      symptoms (Inventory of Depressive Symptomatology [IDS]) and insulin sensitivity
      (M-value derived from the results of a hyperinsulinemic-euglycemic clamp).
      Secondary outcomes were related psychological and glucometabolic measures.
      RESULTS: Intention-to-treat analysis showed that light therapy was not superior
      to placebo in reducing depressive symptoms (-3.9 IDS points [95% CI -9.0 to 1.2];
      P = 0.248) and had no effect on insulin sensitivity (0.15 mg/kg*min [95% CI -0.41
      to 0.70]; P = 0.608). Analyses incorporating only those participants who
      accurately adhered to the light therapy protocol (n = 51) provided similar
      results, but did suggest positive effects of light therapy on depression response
      rates (>/=50% reduction in IDS points) (26% more response; P = 0.031).
      Prespecified analysis showed effect moderation by baseline insulin sensitivity (P
      = 0.009) and use of glucose-lowering medication (P = 0.023). Light therapy did
      not affect depressive symptoms in participants with higher insulin sensitivity or
      those who use only oral glucose-lowering medication or none at all, but it did
      produce a relevant effect in participants with lower insulin sensitivity (-12.9
      IDS points [95% CI -21.6 to -4.2]; P = 0.017) and a trend toward effectiveness in
      those using insulin (-12.2 IDS points [95% CI -21.3 to -3.1]; P = 0.094). Light
      therapy was well tolerated. CONCLUSIONS: Although this trial is essentially
      inconclusive, secondary analyses indicate that light therapy might be a promising
      treatment for depression among a subgroup of highly insulin-resistant individuals
      with type 2 diabetes.
CI  - (c) 2019 by the American Diabetes Association.
FAU - Brouwer, Annelies
AU  - Brouwer A
AUID- ORCID: http://orcid.org/0000-0001-7195-2840
AD  - Amsterdam UMC, Vrije Universiteit, and GGZ inGeest, Department of Psychiatry,
      Amsterdam Public Health research institute, Amsterdam, the Netherlands
      a.brouwer1@vumc.nl.
FAU - van Raalte, Daniel H
AU  - van Raalte DH
AD  - Amsterdam UMC, Vrije Universiteit, Department of Internal Medicine, Diabetes
      Center, Amsterdam, the Netherlands.
FAU - Nguyen, Hoang-Ton
AU  - Nguyen HT
AD  - Amsterdam UMC, Vrije Universiteit, Department of Ophthalmology, Amsterdam, the
      Netherlands.
FAU - Rutters, Femke
AU  - Rutters F
AD  - Amsterdam UMC, Vrije Universiteit, Department of Epidemiology and Biostatistics, 
      Amsterdam Public Health research institute, Amsterdam, the Netherlands.
FAU - van de Ven, Peter M
AU  - van de Ven PM
AD  - Amsterdam UMC, Vrije Universiteit, Department of Epidemiology and Biostatistics, 
      Amsterdam Public Health research institute, Amsterdam, the Netherlands.
FAU - Elders, Petra J M
AU  - Elders PJM
AD  - Amsterdam UMC, Vrije Universiteit, Department of General Practice and Elderly
      Care Medicine, Amsterdam Public Health research institute, Amsterdam, the
      Netherlands.
FAU - Moll, Annette C
AU  - Moll AC
AD  - Amsterdam UMC, Vrije Universiteit, Department of Ophthalmology, Amsterdam, the
      Netherlands.
FAU - Van Someren, Eus J W
AU  - Van Someren EJW
AD  - Amsterdam UMC, Vrije Universiteit, and GGZ inGeest, Department of Psychiatry,
      Amsterdam Public Health research institute, Amsterdam, the Netherlands.
AD  - Netherlands Institute for Neuroscience, Department of Sleep and Cognition,
      Amsterdam, the Netherlands.
AD  - Amsterdam UMC, Vrije Universiteit, Department of Integrative Neurophysiology,
      Centre for Neurogenomics and Cognitive Research, Neuroscience Campus Amsterdam,
      Amsterdam, the Netherlands.
FAU - Snoek, Frank J
AU  - Snoek FJ
AD  - Amsterdam UMC, Vrije Universiteit and University of Amsterdam, Department of
      Medical Psychology, Amsterdam Public Health research institute, Amsterdam, the
      Netherlands.
FAU - Beekman, Aartjan T F
AU  - Beekman ATF
AD  - Amsterdam UMC, Vrije Universiteit, and GGZ inGeest, Department of Psychiatry,
      Amsterdam Public Health research institute, Amsterdam, the Netherlands.
FAU - Bremmer, Marijke A
AU  - Bremmer MA
AD  - Amsterdam UMC, Vrije Universiteit, and GGZ inGeest, Department of Psychiatry,
      Amsterdam Public Health research institute, Amsterdam, the Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20190222
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2019/02/24 06:00
MHDA- 2019/02/24 06:00
CRDT- 2019/02/24 06:00
PHST- 2018/08/14 00:00 [received]
PHST- 2019/01/19 00:00 [accepted]
PHST- 2019/02/24 06:00 [pubmed]
PHST- 2019/02/24 06:00 [medline]
PHST- 2019/02/24 06:00 [entrez]
AID - dc18-1732 [pii]
AID - 10.2337/dc18-1732 [doi]
PST - ppublish
SO  - Diabetes Care. 2019 Apr;42(4):529-538. doi: 10.2337/dc18-1732. Epub 2019 Feb 22.